论文部分内容阅读
应用ＬＳＡＢ免疫组化方法检测了１１７例非小细胞肺癌组织中ｐ５３、ｐ１６基因蛋白的表达。结果显示：ｐ５３、ｐ１６蛋白在肺癌中的阳性表达率分别为４９．６％、４５．３％；在不同组织学类型中，２种蛋白阳性表达率均无显著性差异；ｐ５３蛋白表达与肺腺癌淋巴结转移有显著相关性，ｐ５３蛋白阳性表达者的淋巴结转移能力强（Ｐ＜０．０５）；ｐ５３、ｐ１６蛋白表达与患者预后有关，ｐ５３蛋白阳性表达及ｐ１６蛋白阴性表达者预后差（Ｐ＜０．０５）。结果表明：ｐ５３、ｐ１６基因改变在非小细胞肺癌的发生发展中起重要作用，ｐ５３、ｐ１６蛋白异常表达可作为判断肺癌患者预后的有效指标。
LSAB immunohistochemistry was used to detect the expression of p53 and p16 protein in 117 non-small cell lung cancer tissues. The results showed that the positive expression rates of p53 and p16 in lung cancer were 49.6% and 45.3%, respectively; in different histological types, there was no significant difference in the positive expression rates of the two proteins; p53 protein expression and lung The lymph node metastasis of adenocarcinoma was significantly correlated. The lymph node metastasis of p53 protein positive expression was strong (P<0.05). The expression of p53 and p16 protein was related to the prognosis of patients. The positive expression of p53 protein and the negative expression of p16 protein were poor. P<0.05). The results showed that the changes of p53 and p16 genes play an important role in the development of non-small cell lung cancer. The abnormal expression of p53 and p16 proteins can be used as an effective index to judge the prognosis of lung cancer patients.